Victoria Divino et al, Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice, Presentation for ESC-2025, ESC 2025: Novo Nordisks Wegovy superior to Zepbound in reducing CV events, Clinical Trial Arena, 01 September 2025,
The FDA is still in the process of finalizing its approved bulk drug substances lists
The only study that has investigated the effects of selenium supplementation in Graves ophthalmopathy and led to introduction of selenium supplementation in Graves ophthalmopathy
While Semaglutide is a great help in losing weight, its not a one-stop solution
Our score: 4/5 Heres how we rated Calibrate on what matters most when choosing a weight-loss clinic: Wait
In this study, we used a large electronic health record (EHR) database encompassing over 1.2 million T2DM patients in the U.S